193 related articles for article (PubMed ID: 2557897)
1. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.
Drake FH; Hofmann GA; Bartus HF; Mattern MR; Crooke ST; Mirabelli CK
Biochemistry; 1989 Oct; 28(20):8154-60. PubMed ID: 2557897
[TBL] [Abstract][Full Text] [Related]
2. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme.
Drake FH; Zimmerman JP; McCabe FL; Bartus HF; Per SR; Sullivan DM; Ross WE; Mattern MR; Johnson RK; Crooke ST
J Biol Chem; 1987 Dec; 262(34):16739-47. PubMed ID: 2824504
[TBL] [Abstract][Full Text] [Related]
3. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
[TBL] [Abstract][Full Text] [Related]
4. Association between the p170 form of human topoisomerase II and progeny viral DNA in cells infected with herpes simplex virus type 1.
Ebert SN; Subramanian D; Shtrom SS; Chung IK; Parris DS; Muller MT
J Virol; 1994 Feb; 68(2):1010-20. PubMed ID: 8289331
[TBL] [Abstract][Full Text] [Related]
5. Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase.
Kimura K; Saijo M; Ui M; Enomoto T
J Biol Chem; 1994 Jan; 269(2):1173-6. PubMed ID: 8288578
[TBL] [Abstract][Full Text] [Related]
6. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.
Bigioni M; Zunino F; Tinelli S; Austin CA; Willmore E; Capranico G
Biochemistry; 1996 Jan; 35(1):153-9. PubMed ID: 8555169
[TBL] [Abstract][Full Text] [Related]
7. Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage.
Fortune JM; Osheroff N
J Biol Chem; 1998 Jul; 273(28):17643-50. PubMed ID: 9651360
[TBL] [Abstract][Full Text] [Related]
8. The distribution of immunoreactive topoisomerase II Protein in human tissues and neoplasms.
Holden JA; Rolfson DH; Wittwer CT
Oncol Res; 1992; 4(4-5):157-66. PubMed ID: 1324031
[TBL] [Abstract][Full Text] [Related]
9. Quantitative adaptation of the bacteriophage P4 DNA unknotting assay for use in the biochemical and pharmacological characterization of topoisomerase II.
Hofmann GA; Mirabelli CK; Drake FH
Anticancer Drug Des; 1990 Aug; 5(3):273-82. PubMed ID: 2169250
[TBL] [Abstract][Full Text] [Related]
10. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
Cornarotti M; Tinelli S; Willmore E; Zunino F; Fisher LM; Austin CA; Capranico G
Mol Pharmacol; 1996 Dec; 50(6):1463-71. PubMed ID: 8967966
[TBL] [Abstract][Full Text] [Related]
11. The catalytic activities of DNA topoisomerase II are most closely associated with the DNA cleavage/religation steps.
Scala D; Escargueil AE; Couprie J; Larsen AK
Biochimie; 1999 Jul; 81(7):771-9. PubMed ID: 10492025
[TBL] [Abstract][Full Text] [Related]
12. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
13. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Robinson MJ; Corbett AH; Osheroff N
Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
[TBL] [Abstract][Full Text] [Related]
14. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.
Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N
Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339
[TBL] [Abstract][Full Text] [Related]
15. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
Thielmann HW; Popanda O; Gersbach H; Gilberg F
Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
[TBL] [Abstract][Full Text] [Related]
16. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
17. Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.
Woessner RD; Chung TD; Hofmann GA; Mattern MR; Mirabelli CK; Drake FH; Johnson RK
Cancer Res; 1990 May; 50(10):2901-8. PubMed ID: 2159365
[TBL] [Abstract][Full Text] [Related]
18. Sequence dependence of Drosophila topoisomerase II in plasmid relaxation and DNA binding.
Sander M; Hsieh T; Udvardy A; Schedl P
J Mol Biol; 1987 Mar; 194(2):219-29. PubMed ID: 3039151
[TBL] [Abstract][Full Text] [Related]
19. Effects of nucleosomes and anti-tumor drugs on the catalytic activity of type II DNA topoisomerase from rat testis.
Galande S; Muniyappa K
Biochem Pharmacol; 1997 May; 53(9):1229-38. PubMed ID: 9214683
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
